1Kannel WB, Abbott RD, Savage DD, et ah Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med. 1982,306 : 1018-1022.
2Benjamin EJ, Wolf PA D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998.98:946-952.
3Bruins P, Velthuis H, Yazdanbakhsh AP. et al. Activation of the complement system during and after cardiopuhnonary bypass surgeD': postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997,96: 3542 -3548.
4Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001, 104:2886-2891.
5Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108: 3006-3010.
6Sata N, Hamada N, tIorinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J, 2004,45:441-445.
7Frustaci A, Chimenfi C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997,96:1180-1184.
8Voros S, Yang Z, Bove CM,et al. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. Am J Physiol Heart Circ Physiol, 2006,290:H1004-H1010.
10Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardic fibroblast: response to angiotensin Ⅱ and aldosterone. J Mol Cell Cardiol, 1994,26:809-820.
二级参考文献20
1[1]Roy D,Talajic M,Dorian P, et al. Amiodarnoe to prevent recurrence of atrial fibrillation. Canadian Trial of atrial fibrillation Investigators. N Engl J Med, 2000,342: 913-920.
2[2]Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol, 1998,81:995-998.
3[3]Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation, 1995,92:1954-1968.
4[4]Goette A, Honeycutt C,Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation, 1996, 94: 2968-2974.
5[5]Tieleman RG, Langen CDJD, Gelder ICV, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation, 1997,95:1945-1953.
6[6]Wijffels MCEF, Kirchhol CJHJ, Dorland R, et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats:role of neurohumoral changes,ischemia,atrial stretch,and high rate of electrical activation. Circulation, 1997,96: 3710-3720.
7[7]Tieleman RG, Gelder ICV, Crijns HJGM, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-reduced electrical remodeling of atria? J Am Coll Cardil, 1998,31:167-173.
8[8]Van Den Berg MP, Crijns HJGM, Van Veldhuisen DJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail, 1995,1: 355-364.
9[9]Hideko N, Koickiro K, Hidenori U, et al. Angiotensin Ⅱ antagonist prevents electrical remodeling in atrial fibrillation. Circulation, 2000, 101:2612-2617.
10[10]Goette A, Amdt M, Rocken C, et al. Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in human. Circulation, 2000,101:2678-2681.
